So far this year, 13 companies have gone public via direct listing, marking the biggest year ever for the IPO alternative. Nearly half have come to market in the past two months. But the year’s direct listings average a dismal -71% return from first trade,...read more
Lakewood-Amedex Biotherapeutics, which is developing a topical antimicrobial treatment for drug-resistant infections, completed its direct listing on the Nasdaq on Thursday. Shares of common stock were sold by existing shareholders; the company did not raise...read more
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more
Lakewood-Amedex Biotherapeutics, which is developing a topical antimicrobial treatment for drug-resistant infections, filed on Friday for a direct listing on the Nasdaq. The shares of common stock listed will be sold by existing shareholders;...read more
Direct listings are having a record year, but performance tells a different story
So far this year, 13 companies have gone public via direct listing, marking the biggest year ever for the IPO alternative. Nearly half have come to market in the past two months. But the year’s direct listings average a dismal -71% return from first trade,...read more
Micro-cap antimicrobial developer Lakewood-Amedex Biotherapeutics completes Nasdaq direct listing
Lakewood-Amedex Biotherapeutics, which is developing a topical antimicrobial treatment for drug-resistant infections, completed its direct listing on the Nasdaq on Thursday. Shares of common stock were sold by existing shareholders; the company did not raise...read more
US IPO Weekly Recap: Aktis Oncology leads as first sizable 2026 IPO
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more
Micro-cap biotech Lakewood-Amedex Biotherapeutics files for a Nasdaq direct listing
Lakewood-Amedex Biotherapeutics, which is developing a topical antimicrobial treatment for drug-resistant infections, filed on Friday for a direct listing on the Nasdaq. The shares of common stock listed will be sold by existing shareholders;...read more